期刊文献+

肺靶向吡非尼酮脂质体的制备及体外释药性质研究 被引量:5

Study on preparation and in vitro release behavior of lung targeting perfenidone liposomes
下载PDF
导出
摘要 目的:研究肺靶向吡非尼酮脂质体的制备方法并考察其体外释药性质。方法:采用薄膜分散法制备吡非尼酮脂质体;用D-甘露糖修饰脂质体并添加适量十八胺调节脂质体表面电荷;用紫外分光光度法测定包封率;用正交实验优化处方,用透析法考察药物体外释放性质。结果:制得的脂质体平均粒径为581.1nm,表面电荷为-20.61mV,包封率为81.1%,稳定性好。药物体外释药符合Weibull方程。结论:采用薄膜分散法,用D-甘露糖修饰并添加十八胺可制得具有较高包封率及稳定性的吡非尼酮脂质体,有助于提高吡非尼酮的肺靶向性。 Objective:To prepare lung targeting perfenidone liposomes and study the release of perfenidone in vitro. Method:The perfenidone liposomes were prepared by thin film method. D--mannose was used to coat the liposomes for lung targeting action and lipid membrane was modified with stearylamine. UV method was used to determine the entrapment efficiency of perfenidone liposomes. Orthogonal design was used to select the optimum formulation. Dialysis was used to study the release of perfenidone in vitro. Results:The prepared per- fenidone liposomes demonstrated good stability and encapsulation efficiency was 81.1%. The average size was 581. lnm and the Zeta potential of the modified perfenidone liposomes was --20. 61mV. The release in vitro was characterized by Weibull equation. Conclusion :Thin film method with freeze--thawing steps could increase the entrapment efficiency and stability of perfenidone liposomes after modification of lipid membrane with D-- mannose and stearylamine. It was valuable to be further studied for lung target.
出处 《黑龙江医药科学》 2012年第3期28-30,共3页 Heilongjiang Medicine and Pharmacy
关键词 吡非尼酮 脂质体 肺靶向 perfenidone liposome lung targeting
  • 相关文献

参考文献4

  • 1Raghu G, Johnson WC, Loekhart D,et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent pirfenidone:reaults of a prospective, open--label phase study[J,]. Am J Respir Crit Care Med, 1999,159(4): 1061.
  • 2Regulatory watch. First drug for idiopathic pulmonary fibrosis ap- proved in Japan[J]. Nat Rev Drug Discov, 2008,7(12):966-967.
  • 3毕殿州.药剂学[M].第4版.北京:人民卫生出版社,2000,449-450.
  • 4Laursen S B,Tlhiel S,Teisner B. Bovine conglutin in binds to an oligo saccharide determinant presented by C3b, but not by C3, C3b or C3c[J]. Immunology,1994,81(4) :648-654.

同被引文献29

  • 1李惠萍,李霞,何国钧,易祥华,蔡映云,Charlie Strange.地塞米松对博莱霉素致肺间质纤维化大鼠肺内炎性细胞的影响[J].复旦学报(医学版),2004,31(4):378-382. 被引量:9
  • 2韩世岩,方桂珍,李珊珊,马艳丽.四氢呋喃-苯混合溶剂法分离纯化桦木醇[J].林产化学与工业,2005,25(B10):129-132. 被引量:12
  • 3黄展,谷继伟.恶丙嗪脂质体的制备[J].黑龙江医药科学,2006,29(6):23-24. 被引量:1
  • 4Takator IM. Skin care preparation and application of the same: JP, 2006327966[ P]. 2006,12,07.
  • 5Eom S Y, Jung U S, Kim J H, et al. Cosmetic composition for de- creasing wrinkles comprising betulin: KR, 2003067545 [ P]. 2003, 08,14.
  • 6Kuznetsova S A,Kuznetsov B N, Lebedeva A B, et ai, Capillary re- storative agent: RU, 2276980[ P]. 2006,05,27.
  • 7LiS Z, Zhang B. The chemistry of Z iz ip hus jujuba manages to study the general situation with the medicine [ J ]. Chi Trad it Herb,1983, 14 (10) : 39-43.
  • 8Takakuta Koji, Fujimori Akira, Chikanishi Toshihiro, et al. Renopro- tective properties of pirfenidone in subtotally nephrectomized rats [J]. European Journal of Pharmacology, 2010,629 ( 1 - 3 ) : 118 - 124.
  • 9Koji Takakura, Kazuhiko Mizukami, Hikaru Mitori. Antiproteinuric effect of pirfenidone in a rat model of anti - glomerular basement membrane glomerulonephritis [ J ]. European Journal of Pharmacolo- gy ,2014,737 : 106 - 116.
  • 10Ji X, Naito Y, Weng H, et al. Renoproteetive mechanisms of pirfeni- done in hypertension - indueod renal injury: through anti - fibrotie and anti - oxidative stress pathways [ J ]. Biomed Res,2013,34 (6) : 309 - 319.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部